to quarter today we all sales a Thank XX% with thank year-over-year, increase revenue. report for a you, be Matt. I'm you and growth total excited as in afternoon, catheter XX% driving up strong joining you with Good us.
the availability, for new launched quarter. we weeks into saw Pantheris this to limited XX the sites the distribution was SV, Pantheris product which third quarter, revenue we quarter released Despite During X this of demand in contribution first the the from in national the the in in third the last SV showcasing market.
of increased increase a penetration expect an differentiated to to the full product fourth to provide availability in our new revenue continue this account We and contribution SV highly Pantheris quarter with quarter. base of into
for there sales and Pantheris While contributed lumivascular year-over-year. by of very go-to a treatment launch, to lot we mid next-generation procedures the around last Pantheris Pantheris option vessels, performed. device excitement majority primarily for above year, knee, of the in catheter, the was seven-French to physicians' continues increasing SV the be are and in this atherectomy activity quarter our successful market launched with meaningfully third seven-French the also larger is growth our XX% the which where
in of trend We're line includes new versus second to our third in quarters Pantheris and $XXX,XXX Total for XX% potential million, XX% quarter-over-quarter revenue product about year-over-year Pantheris very to the revenue increased which the to growth products with response are drive this from market over Pantheris pleased SV. important $X.X and higher-margin revenue to our in the of and XX% gross from on improving quarter. we driving in quarter By the XX% first efforts delivering the sales, come. in margin catheter our up sales capital gross XX% margins a focusing quarter, continued the excited
on to efficiencies, operating improve leverage expect as the As we business. growth we continue gain gross to improve we revenue margins operating accelerate to and continue
few progress highlights during me on provide we quarter. other a made Let the the
through sites key First, of and XX-or-so opinion immediate SV to feedback below the a the the the product in put real-world device cases to Physicians clinical knee. These to difficult the us leader in XX treating in device limited evaluate to treating cases setting. This especially select performing support device vessels, of enabled we arteries also clinical training the launch on rollout efficacy first Pantheris safety the national exceptionally And paces, small launch. July received well and well began for gave of reach and the process challenging delivering supporting is prepared prior outcomes. a positive our the and device. to its to limited refine with our lesions us utilization PAD we're variety programs the team clinical that continued confident building this and SV in rollout of opportunity
anticipate as began contributor new this options to the and treatment to for PAD have that's potentially third therapeutic limited this quarter, our effort innovative severe fourth meaningful the and come. commercial be into strategy late an Clearly, launch straight we for where it demand there's years growth platform, sites to We consequences, patient in they a full untreated. continued if embrace left quarter for
Pantheris expansion In ongoing the growth our we launch supported markets, PAD sales in team. in expanded by X of sites the Arizona. customer the is addition to by account quarter launching Georgia This of Florida, in new new sites and the of third high-volume SV, including base our clinical markets key
quarter XX At we XX sales ago. were headcount, end, from year up at a
in team account support We accelerate our and our expand is are base ensure to more optimal to cases our to working further at locations placed sales top growth. centers
As as learning our are our the specialists and devices. come increasing quarter productivity our new with fourth on become XXXX curve in hires new into up experienced reps platform, and see more focused we productivity the clinical and with sales improving
now a RPM, and for the some launch is designed crossing which of cases. that for crossing product physician's the CTOs and catheter range to current true enhance platform, to successful challenging new wider a is improvements designed are enhanced X,XXX CTOs. of the a significant extension Pantheris to up at Ocellaris, all product, on and next of image-guided to steerable chronic Ocelot we severe the ability maneuverability, believe SV, our our for a or bring product of launch. is our blocked market total of tip Ocellaris which PAD family precise pipeline catheters for including of of speeds most development arteries With ability focused represent preparing imaging, luminal next-generation will spin Ocellaris occlusions, team completely is
of program Ocellaris the with follow for a Similar months. to anticipated structured several we a Pantheris number important next SV, plan milestones launch over to
CE we which first Ocellaris us receiving later leader Europe. for opinion would First, sites allow this in at initiate cases to anticipate Marking quarter, key
year. receive then Europe, according in national first proceed case be of we submitting initial U.S. the experience clearance submission this peripheral in we the all If use launch goes of to Following a XXX(k) hope in a position in Ocellaris the full XXXX. and launch and next to for anticipate to arteries the in limited plan, to to pre-marketing FDA half U.S.
tool coming give business platform the and grow to approvals will us look key securing forward cases We required accelerate CTO to begin our sites believe innovative to months. the this elegant in at and and the
that's As large coronary look to market also and we the valuable in arteries, to technology to for we CTOs address potential this apply future, of today. a see the the the difficult advanced treatment
experience coronary gain updates we with providing in applications. the on forward progress As peripheral in Ocellaris developing arteries, our look we to
data have made treatment good evaluate released our the at restenosis been we INSIGHT the in quarter, over preliminary lower Early extremity including results progress also to in study programs arteries. for trial. Pantheris our clinical on IDE conference of that very encouraging, the This in-stent the We've designed or past ISR clinical CVC is starting with July.
and or the of XX XX% greater alone showed blockage average therapy. after XX% a stenosis study in The the the use use first the Pantheris in following than reduction a of enrolled patients adjunctive reduction
ISR submit XXX(k) of a half of XXXX in the application to complete lesion next from We enrollment a is this label the and specifically to in FDA TLR, to Freedom in being hope anticipate by first after expand group. to which include was target the revascularization XX% of restenosis, to or position the in study the our patient indicator an months year indication. end X INSIGHT
are and in enrollment and clinical small compelling support as device, on outcomes what a generate very Pantheris also preparing data for experience clinical best-in-class We this SV to of with quarter. treatment initial believe expect study in vessel Based this initiate Pantheris clinical for post-market disease. be a a later study we're initiate SV will to setting our real-world to efficacy safety we excited
We've in meaningful quarters, translating past for made significant with drivers upside our the against is several over growth quarter which to milestones progress third and quarters. initiatives growth the subsequent revenue strategic progress,
utilization off to is our device coming gain market Our adoption, to revenue next-generation and generate SV onboard us market and source more centers of clear cases exciting sites interest with continues in sites current PAD the Pantheris increased start at enabling a each driving to Pantheris an even new sites. growth. of new treat new week and launch
continue we and highly a treatment lean revenue do approach support expand model to new build pipeline comprehensive operating generate of leverageable of strong compelling a for business and we structure lumivascular We provide solution and products the to with so to grow of further disease. as cost clinical margins. vascular data And in PAD our a continue to
this and our At let come and Q&A. ask point, me Mark to Mark? pause then I'll for back financials, cover
